Trade RNTX stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Rein Therapeutics, Inc. (RNTX) is trading at US$0.78, down 5.63% today as of Sep 10, 16:00 EDT. The company has a market capitalisation of US$70.57M. Over the past 52 weeks, RNTX has traded between US$0.69 and US$2.18. On Syfe you can trade RNTX with $0 commission and add it to your watchlist.
| Previous close | US$0.83 |
|---|---|
| Market cap | US$70.57M |
| 52-week range | US$0.69 – US$2.18 |
| Volume | 240.57K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Rein Therapeutics, Inc.
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
Year: 2017
Rein Therapeutics Completes Global Expansion of Phase 2 IPF Trial
Jul 21, 12:24 PM · MT Newswires
Rein Therapeutics Prices $50 Million Common Stock Offering; Shares Down Pre-Bell
May 1, 10:16 AM · MT Newswires
Rein Therapeutics, Inc. (RNTX) stock is trading at US$0.78, -5.63% from the previous close of US$0.83.
The market cap for Rein Therapeutics, Inc. (RNTX) stock is approximately US$70.57M.
The 52-week high for Rein Therapeutics, Inc. (RNTX) stock is US$2.18.
The 52-week low for Rein Therapeutics, Inc. (RNTX) stock is US$0.69.
Rein Therapeutics, Inc. (RNTX) does not currently pay a dividend.
Stay on top of RNTX
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
